V Square Quantitative Management LLC Buys 193 Shares of Cencora, Inc. $COR

V Square Quantitative Management LLC increased its stake in shares of Cencora, Inc. (NYSE:COR) by 5.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 3,925 shares of the company’s stock after buying an additional 193 shares during the period. V Square Quantitative Management LLC’s holdings in Cencora were worth $1,177,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Voleon Capital Management LP bought a new stake in shares of Cencora during the first quarter worth approximately $3,111,000. Exchange Traded Concepts LLC boosted its stake in Cencora by 4.5% in the 1st quarter. Exchange Traded Concepts LLC now owns 1,104 shares of the company’s stock valued at $307,000 after purchasing an additional 48 shares during the period. Focus Partners Wealth boosted its stake in Cencora by 25.8% in the 1st quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock valued at $1,589,000 after purchasing an additional 1,171 shares during the period. Fiduciary Alliance LLC acquired a new position in Cencora in the 2nd quarter valued at $262,000. Finally, Martin Capital Partners LLC increased its position in Cencora by 205.2% during the 2nd quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock worth $1,135,000 after buying an additional 2,544 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley set a $330.00 target price on shares of Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. Wells Fargo & Company raised their target price on shares of Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a report on Wednesday, August 13th. Finally, Jefferies Financial Group boosted their price target on Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a report on Monday, June 30th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and a consensus target price of $311.25.

Cencora Trading Up 0.4%

COR opened at $308.12 on Tuesday. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. Cencora, Inc. has a fifty-two week low of $218.65 and a fifty-two week high of $310.00. The company’s 50 day moving average price is $293.31 and its two-hundred day moving average price is $289.17. The firm has a market capitalization of $59.74 billion, a price-to-earnings ratio of 31.70, a PEG ratio of 1.56 and a beta of 0.62.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.21. The firm had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter last year, the firm earned $3.34 earnings per share. As a group, research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, August 15th. Cencora’s dividend payout ratio (DPR) is 22.63%.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction that occurred on Thursday, September 18th. The stock was sold at an average price of $290.00, for a total value of $1,478,130.00. Following the sale, the chief executive officer directly owned 39,274 shares in the company, valued at $11,389,460. This represents a 11.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 55,993 shares of company stock worth $16,292,923. 10.80% of the stock is owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.